Abstract
Highly active antiretroviral therapy prolongs the life of HIV-infected individuals, but it requires lifelong treatment and results in cumulative toxicities and viral-escape mutants. Gene therapy offers the promise of preventing progressive HIV infection by sustained interference with viral replication in the absence of chronic chemotherapy. Gene-targeting strategies are being developed with RNA-based agents, such as ribozymes, antisense, RNA aptamers and small interfering RNA, and protein-based agents, such as the mutant HIV Rev protein M10, fusion inhibitors and zinc-finger nucleases. Recent advances in T-cell–based strategies include gene-modified HIV-resistant T cells, lentiviral gene delivery, CD8+ T cells, T bodies and engineered T-cell receptors. HIV-resistant hematopoietic stem cells have the potential to protect all cell types susceptible to HIV infection. The emergence of viral resistance can be addressed by therapies that use combinations of genetic agents and that inhibit both viral and host targets. Many of these strategies are being tested in ongoing and planned clinical trials.
Similar content being viewed by others
References
Deeks, S.G. Antiretroviral treatment of HIV infected adults. Br. Med. J. 332, 1489 (2006).
Phillips, A.N., Gazzard, B.G., Clumeck, N., Losso, M.H. & Lundgren, J.D. When should antiretroviral therapy for HIV be started? Br. Med. J. 334, 76–78 (2007).
Sarver, N. et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222–1225 (1990).
Michienzi, A. et al. RNA-mediated inhibition of HIV in a gene therapy setting. Ann. NY Acad. Sci. 1002, 63–71 (2003).
Ngok, F.K. et al. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol. Biol. 252, 581–598 (2004).
Bauer, G. et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1–infected donors using retroviral vectors containing anti–HIV-1 genes. Blood 89, 2259–2267 (1997).
Leavitt, M.C. et al. Transfer of an anti–HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther. 5, 1115–1120 (1994).
Chatterjee, S., Johnson, P.R. & Wong, K.K., Jr . Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 258, 1485–1488 (1992).
Levine, B.L. et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103, 17372–17377 (2006).
Lu, X. et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1–based vector results in severely attenuated mutants incapable of developing resistance. J. Virol. 78, 7079–7088 (2004).
Held, D.M., Kissel, J.D., Patterson, J.T., Nickens, D.G. & Burke, D.H. HIV-1 inactivation by nucleic acid aptamers. Front. Biosci. 11, 89–112 (2006).
Joshi, P.J., Fisher, T.S. & Prasad, V.R. Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr. Drug Targets Infect. Disord. 3, 383–400 (2003).
Symensma, T.L., Giver, L., Zapp, M., Takle, G.B. & Ellington, A.D. RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J. Virol. 70, 179–187 (1996).
Kohn, D.B. et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1–infected children. Blood 94, 368–371 (1999).
Hannon, G.J. & Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature 431, 371–378 (2004).
Jacque, J.M., Triques, K. & Stevenson, M. Modulation of HIV-1 replication by RNA interference. Nature 418, 435–438 (2002).
Lee, N.S. et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20, 500–505 (2002).
Martinez, M.A., Clotet, B. & Este, J.A. RNA interference of HIV replication. Trends Immunol. 23, 559–561 (2002).
Novina, C.D. et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681–686 (2002).
Coburn, G.A. & Cullen, B.R. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76, 9225–9231 (2002).
Boden, D., Pusch, O., Lee, F., Tucker, L. & Ramratnam, B. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77, 11531–11535 (2003).
Westerhout, E.M., Ooms, M., Vink, M., Das, A.T. & Berkhout, B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 33, 796–804 (2005).
Das, A.T. et al. Human immunodeficiency virus type 1 escapes from RNA interference–mediated inhibition. J. Virol. 78, 2601–2605 (2004).
Sabariegos, R., Gimenez-Barcons, M., Tapia, N., Clotet, B. & Martinez, M.A. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J. Virol. 80, 571–577 (2006).
Anderson, J. & Akkina, R. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology 2, 53 (2005).
Cordelier, P., Morse, B. & Strayer, D.S. Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. Oligonucleotides 13, 281–294 (2003).
Surabhi, R.M. & Gaynor, R.B. RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J. Virol. 76, 12963–12973 (2002).
An, D.S. et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol. Ther. 14, 494–504 (2006).
Garred, P. et al. Dual effect of CCR5 delta 32 gene deletion in HIV-1–infected patients. Copenhagen AIDS Study Group. Lancet 349, 1884 (1997).
Samson, M. et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722–725 (1996).
Huang. Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240–1243 (1996).
Lapidot, T. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2m null NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann. NY Acad. Sci. 938, 83–95 (2001).
Lapidot, T. & Kollet, O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16, 1992–2003 (2002).
Kahn, J. et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 103, 2942–2949 (2004).
Ariën, K.K. et al. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones. Virology 347, 65–74. (2006).
Chang, L.J., Liu, X. & He, J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther. 12, 1133–1144 (2005).
Berkhout, B. & Haasnoot, J. The interplay between virus infection and the cellular RNA interference machinery. FEBS Lett. 580, 896–902 (2006).
Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537–541 (2006).
Li, M.J. et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900–909 (2005).
Unwalla, H.J. et al. Novel Pol II fusion promoter directs human immunodeficiency virus type 1–inducible coexpression of a short hairpin RNA and protein. J. Virol. 80, 1863–1873 (2006).
Woffendin, C., Ranga, U., Yang, Z., Xu, L. & Nabel, G.J. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus–infected patients. Proc. Natl. Acad. Sci. USA 93, 2889–2894 (1996).
Lobato, M.N. & Rabbitts, T.H. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr. Mol. Med. 4, 519–528 (2004).
Marasco, W.A., LaVecchio, J. & Winkler, A. Human anti–HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J. Immunol. Methods 231, 223–238 (1999).
Poluri, A., van Maanen, M. & Sutton, R.E. Genetic therapy for HIV/AIDS. Expert Opin. Biol. Ther. 3, 951–963 (2003).
Schroers, R., Davis, C.M., Wagner, H.J. & Chen, S.Y. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther. 9, 889–897 (2002).
Yang, A.G., Bai, X., Huang, X.F., Yao, C. & Chen, S. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc. Natl. Acad. Sci. USA 94, 11567–11572 (1997).
Egelhofer, M. et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 78, 568–575 (2004).
Perez, E.E., Riley, J.L., Carroll, R.G., von Laer, D. & June, C.H. Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clin. Immunol. 115, 26–32 (2005).
Mani, M., Kandavelou, K., Dy, F.J., Durai, S. & Chandrasegaran, S. Design, engineering, and characterization of zinc finger nucleases. Biochem. Biophys. Res. Commun. 335, 447–457 (2005).
Lombardo, A. et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298–1306 (2007).
Levine, B.L. et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939–1943 (1996).
Levine, B.L. et al. Effects of CD28 costimulation on long term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921–5930 (1997).
Carroll, R.G. et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 276, 273–276 (1997).
Bex, F. et al. Syngeneic adoptive transfer of anti–human immunodeficiency virus-1 (HIV-1)–primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1–infected identical twin. Blood 84, 3317–3326 (1994).
Levine, B.L. et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8, 47–53 (2002).
Fearon, D.T., Manders, P. & Wagner, S.D. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 293, 248–250 (2001).
Barber, D.L., Wherry, E.J. & Ahmed, R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171, 27–31 (2003).
Muul, L.M. et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101, 2563–2569 (2003).
Lund, O. et al. Gene therapy of T helper cells in HIV infection: mathematical model of the criteria for clinical effect. Bull. Math. Biol. 59, 725–745 (1997).
von Laer, D., Hasselmann, S. & Hasselmann, K. Impact of gene-modified T cells on HIV infection dynamics. J. Theor. Biol. 238, 60–77 (2006).
Weinberger, L.S., Schaffer, D.V. & Arkin, A.P. Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J. Virol. 77, 10028–10036 (2003).
Lalezari, J.P. et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir. Ther. 8, 279–287 (2003).
van Lunzen, J. et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther. 15, 1024–1033 (2007).
Masiero, S. et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 12, 299–310 (2005).
Briz, V., Poveda, E. & Soriano, V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 57, 619–627 (2006).
Strayer, D.S. et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol. Ther. 11, 823–842 (2005).
Swan, C.H. & Torbett, B.E. Can gene delivery close the door to HIV-1 entry after escape? J. Med. Primatol. 35, 236–247 (2006).
Luis, A.J. et al. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol. Ther. 8, 475–484 (2003).
Swan, C.H., Buhler, B., Tschan, M.P., Barbas, C.F., III & Torbett, B.E. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther. 13, 1480–1492 (2006).
Bai, J. et al. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. Chem. 278, 1433–1442 (2003).
BouHamdan, M. et al. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther. 8, 408–418 (2001).
Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848–853 (2004).
Luban, J. & Cyclophilin, A. TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. 81, 1054–1061 (2007).
Li, Y., Li, X., Stremlau, M., Lee, M. & Sodroski, J. Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 80, 6738–6744 (2006).
Ranga, U. et al. Retroviral delivery of an antiviral gene in HIV-infected individuals. Proc. Natl. Acad. Sci. USA 95, 1201–1206 (1998).
Morgan, R.A. et al. Preferential survival of CD4+ T lymphocytes engineered with anti–human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum. Gene Ther. 16, 1065–1074 (2005).
Macpherson, J.L. et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J. Gene Med. 7, 552–564 (2005).
Amado, R.G. et al. Anti–human immunodeficiency virus hematopoietic progenitor cell–delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1–infected patients. Hum. Gene Ther. 15, 251–262 (2004).
VandenDriessche, T. et al. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 69, 4045–4052 (1995).
Veres, G. et al. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J. Virol. 72, 1894–1901 (1998).
Humeau, L.M. et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther. 9, 902–913 (2004).
Schroder, A.R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521–529 (2002).
Dave, U.P., Jenkins, N.A. & Copeland, N.G. Gene therapy insertional mutagenesis insights. Science 303, 333 (2004).
Sadelain, M. Insertional oncogenesis in gene therapy: how much of a risk? Gene Ther. 11, 569–573 (2004).
Li, M.J. et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III–promoted anti-HIV RNAs. Mol. Ther. 8, 196–206 (2003).
Eberhardy, S.R. et al. Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J. Virol. 80, 2873–2883 (2006).
Kiepiela, P. et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46–53 (2007).
Walter, E.A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038–1044 (1995).
Heslop, H.E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus–specific T lymphocytes. Nat. Med. 2, 551–555 (1996).
Brodie, S.J. et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J. Clin. Invest. 105, 1407–1417 (2000).
Wodarz, D. & Nowak, M.A. Specific therapy regimes could lead to long-term immunological control of HIV. Proc. Natl. Acad. Sci. USA 96, 14464–14469 (1999).
Roberts, M.R. et al. Targeting of human immunodeficiency virus–infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 84, 2878–2889 (1994).
Yang, O.O. et al. Lysis of HIV-1–infected cells and inhibition of viral replication by universal receptor T cells. Proc. Natl. Acad. Sci. USA 94, 11478–11483 (1997).
Walker, R.E. et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96, 467–474 (2000).
Mitsuyasu, R.T. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus–infected subjects. Blood 96, 785–793 (2000).
Deeks, S.G. et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination anti-retroviral therapy. Mol. Ther. 5, 788–797 (2002).
Letvin, N.L. & Walker, B.D. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat. Med. 9, 861–866 (2003).
Cooper, L.J., Kalos, M., Lewinsohn, D.A., Riddell, S.R. & Greenberg, P.D. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74, 8207–8212 (2000).
Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
Holler, P.D., Lim, A.R., Cho, B.K., Rund, L.A. & Kranz, D.M. CD8− T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J. Exp. Med. 194, 1043–1052 (2001).
Li, Q.J. et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129, 147–161 (2007).
Boulter, J.M. et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 16, 707–711 (2003).
Shultz, L.D., Ishikawa, F. & Greiner, D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118–130 (2007).
Berges, B.K. et al. HIV-1 infection and Cd4 T cell depletion in the humanized Rag2−/−gamma c−/− (RAG-hu) mouse model. Retrovirology 3, 76 (2006).
van Baarle, D., Tsegaye, A., Miedema, F., & Akbar, A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol. Lett. 97, 19–29 (2005).
June, C.H. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117, 1204–1212 (2007).
Kaech, S.M., Hemby, S., Kersh, E. & Ahmed, R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111, 837–851 (2002).
Mazurier, F. et al. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 103, 545–552 (2004).
Check, E. Pioneering HIV treatment would use interference and gene therapy. Nature 437, 601 (2005).
Bahner, I. et al. Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol. Ther. 15, 76–85 (2007).
Bahner, I., Kearns, K., Hao, Q.L., Smogorzewska, M. & Kohn, D.B. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits HIV-1 replication in the myelomonocytic cells produced in long-term culture. J. Virol. 70, 4352–4360 (1996).
Rosenzweig, M. et al. Intracellular immunization of rhesus CD34+ hematopoietic progenitor cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection. Blood 90, 4822–4831 (1997).
Davis, B.R. et al. Targeted transduction of CD34+ cells by transdominant negative Rev-expressing retrovirus yields partial anti-HIV protection of progeny macrophages. Hum. Gene Ther. 9, 1197–1207 (1998).
Braun, S.E. et al. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells. Mol. Ther. 12, 1157–1167 (2005).
Su, L. et al. Hematopoietic stem cell–based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Blood 89, 2283–2290 (1997).
Bai, J. et al. RNA-based anti–HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol. Ther. 6, 770–782 (2002).
Anderson, J. et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes—CCR5 ribozyme, tat-rev siRNA, and TAR decoy—in SCID-hu mouse-derived T cells. Mol. Ther. 15, 1182–1188 (2007).
An, D.S. et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. USA 104, 13110–13115 (2007).
Zaia, J.A. et al. Autologous stem cell transplantation using retrovirus-transduced peripheral blood progenitor cells in HIV-infected persons: comparison of gene marking post-engraftment with and without myeloablative therapy. Blood 94 Suppl 1, 642a (1999).
Amado, R.G. et al. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum. Gene Ther. 10, 2255–2270 (1999).
Podsakoff, G.M. et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34+ cells. Mol. Ther. 12, 77–86 (2005).
Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413 (2002).
Ott, M.G. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1–EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401–409 (2006).
Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672 (2000).
Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003).
Shepherd, B.E. et al. Hematopoietic stem-cell behavior in nonhuman primates. Blood 110, 1806–1813 (2007).
Payne, K.J. & Crooks, G.M. Immune-cell lineage commitment: translation from mice to humans. Immunity 26, 674–677 (2007).
Wong-Staal, F., Poeschla, E.M. & Looney, D.J. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum. Gene Ther. 9, 2407–2425 (1998).
Kang, E.M. et al. Gene therapy–based treatment for HIV-positive patients with malignancies. J. Hematother. Stem Cell Res. 11, 809–816 (2002).
Barrett, A.D. & Dimmock, N.J. Defective interfering viruses and infections of animals. Curr. Top. Microbiol. Immunol. 128, 55–84 (1986).
Roux, L., Simon, A.E. & Holland, J.J. Effects of defective interfering viruses on virus replication and pathogenesis in vitro and in vivo. Adv. Virus Res. 40, 181–211 (1991).
Mautino, M.R. & Morgan, R.A. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther. 9, 421–431 (2002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.J.R. is scientific advisor to Benitec, Inc., an RNAi gene therapy company, and has patents in the field of HIV gene therapy. C.H.J. receives sponsored research grant support form Sangamo Biosciences, patents and patent applications in the field of HIV gene therapy.
Rights and permissions
About this article
Cite this article
Rossi, J., June, C. & Kohn, D. Genetic therapies against HIV. Nat Biotechnol 25, 1444–1454 (2007). https://doi.org/10.1038/nbt1367
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1367
- Springer Nature America, Inc.
This article is cited by
-
Combination gene therapy for HIV using a conditional suicidal gene with CCR5 knockout
Virology Journal (2021)
-
Editing out HIV: application of gene editing technology to achieve functional cure
Retrovirology (2021)
-
CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4+ T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4+ T cell enrichment in humanized mice
Retrovirology (2019)
-
Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses
Scientific Reports (2017)
-
Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach
Molecular Therapy - Nucleic Acids (2016)